Research licence agreement
Dutch biotech company, Crucell N.V and technology partner DSM Biologics have signed a PER.C6 research licence agreement with AbGenomics Corporation based in Taiwan.
Dutch biotech company, Crucell N.V and technology partner DSM Biologics have signed a PER.C6 research licence agreement with AbGenomics Corporation based in Taiwan. AbGenomics Corporations aims to use the PER.C6 cell line for its R&D and early clinical studies of monoclonal antibodies. "The unique characteristics of the PER.C6 technology as a human cell line combined with the short timeline involved in producing clinical material along with the technology's robustness undoubtedly makes our choice for PER.C6 highly imperative," stated Shih-Yao Lin, president of AbGenomics Corporation. The company will make license payments and annual maintenance fees in exchange for certain rights, under the terms of the agreement.
www.crucell.com
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
